论文部分内容阅读
对93例胃癌患者进行P21ras检测，结果显示P21ras阳性表达率为56%，而高分化腺癌阳性表达率为96%，低分化腺癌28％（P<0．01）。晚期胃癌P21ras阳性表达率为72％，而早期胃癌P21ras阳性表达率为19%（p＜0．01）、阳性表达患者一年内复发占77％，阴性表达患者一年内复发占31%（p<0．05）。随访结果表明．阳性表达患者中位生存期为10．8个月，阴性表达患者中位生存期为19．3个月。本文研究结果揭示胃癌患者出现P21ras阳性表达，尤其在高表达的出现是一种愈后不良的因素，所以对胃癌患者出现P21ras高表达患者术后应密切随访，加强术后的综合治疗。
The detection of P21ras in 93 patients with gastric cancer showed that the positive rate of P21ras was 56%, while the positive rate of well-differentiated adenocarcinoma was 96%, and poorly differentiated adenocarcinoma was 28% (P<0.01). The positive rate of P21ras in advanced gastric cancer was 72%, while the positive rate of P21ras in early gastric cancer was 19% (p<0.01). The positive rate of recurrence was 77% in patients with positive expression, and the recurrence of negative expression was 31% in one year in patients with negative expression (p< 0.05). Follow-up results show. The median survival time was 10.8 months for patients with positive expression and 19.3 months for patients with negative expression. The results of this study reveal that the expression of P21ras is positive in gastric cancer patients, especially in the presence of high expression, which is a poorer factor. Therefore, patients with high expression of P21ras in gastric cancer patients should be followed closely to strengthen postoperative comprehensive treatment.